

Notch-regulated miR-223 targets the aryl hydrocarbon receptor pathway and increases cytokine production in macrophages from rheumatoid arthritis patients

Jesús Ogando, Manuel Tardáguila, Andrea Díaz-Alderete, Alicia Usategui, Vanessa Miranda-Ramos, Dannys Jorge Martínez-Herrera, Lorena de la Fuente María J. García-León, María C. Moreno, Sara Escudero, Juan D. Cañete, María L. Toribio, Ildefonso Cases, Alberto Pascual-Montano, José Luis Pablos, Santos Mañes

The following supplementary material may be found in the online version of this article:

Table S1. Transcription factors predicted to bind to the miR-223 promoter

Table S2. Most probable sites predicted for hsa-miR-223-3p and hsa-miR-223-5p on the human *arnt* gene

Table S3. Clinical characteristics of RA patients

Table S4. List of primers used in the study

Figure S1. Non-validated miR expressed in RA and OA patient macrophages

Figure S2. Notch1 and Notch2 are not differentially expressed in RA and OA macrophages

Figure S3. IKK α is not differentially expressed in RA and OA macrophages

Figure S4. Ingenuity Pathway Analysis of miR-223 targets identified in silico

Figure S5. Forced miR-223 expression does not affect AHR protein levels

Figure S6. AHR target gene expression in synovial macrophages

Figure S7. Correlation between CYP1A1, miR-223 and Notch3 levels

Table S1. Transcription factors predicted to bind to the miR-223 promoter

Transcription factor	Location	Cell type
SRF	66017174-66017482	GM12878
PU1	66018575-66019006	GM12878
EGR1	66009236-66009546	K562
TAF1	66015066-66015773	K562
HEY-1	66015169-66019731	K562
PU1	66018574-66018961	K562

Table S2. Most probable sites predicted for hsa-miR-223-3p and hsa-miR-223-5p on the human *arnt* gene

miRNA	Ensembl transcript ID	Seedmatch details (length/# wobbles/first nt)	Position in 3'-UTR	Prediction algorithm
hsa-miR-223-3p	ENST00000354396	6mer/0/3	1141-1146	FindTar
	ENST00000358595		1526-1531	
	ENST00000471844		79-84	
	ENST00000504358	6mer/1/3	243-248	
hsa-miR-223-5p	ENST00000354396	7mer/1/2	761-767	
	ENST00000358595		1146-1152	
	ENST00000471844		778-785	
	ENST00000354396	8mer/1/3	1163-1170	
	ENST00000358595		2096-2101	
	ENST00000471844		6mer/1/1	

Site position is counted from the beginning of the 3'UTR. Sites conserved in different 3'UTRs were obtained by a multiple sequence alignment using ClustalW v2.1.

Table S3. Clinical characteristics of RA patients

Characteristic	number (% or SD)
Female	8 (73)
Age (SD)	63 (5)
Time of evolution, years (SD)	11 (8)
EROSIONS	8 (73)
RF+	7 (63)
ACPA+	8 (73)
Prednisone	4 (36)
DMARDs	5 (45)*

RF, Rheumatoid factor; ACPA, anti-citrullinated peptide antigen; DMARD, Disease modifying anti-rheumatic drugs; (*) 4 Methotrexate, 1 anti-malarials. No patients were on biologic therapy.

Table S4. List of primers used in the study

Gene	Forward	Reverse
<i>b-act</i>	CCCAGCACAATGAAGATCAA	CCCAGCACAATGAAGATCAA
<i>ikka</i>	TGTGCCTCTTCTAGCAATGGA	TTCTGGTTTGTGAGCAGCTT
<i>hey1</i>	CGAGCTGGACGAGACCAT	CTAGAGCCGAACTCAAGTTTCC
<i>hes1</i>	GTGAAGCACCTCCGGAAC	GTCACCTCGTTCATGCACTC
<i>cyp1a1</i>	CCCAGGCTCCAAGAGTCCACCC	GCCAGAAGAACTCCGTGGCCG
<i>cyp1b1</i>	ACATCTTCGGCGCCAGCCAGG	TCCCTCCCCACGACCTGATCCA
<i>il-6</i>	CGGGAACGAAAGAGAAGCTCTA	GGCGCTTGTGGAGAAGGAG
<i>il-1β</i>	CCCTAAACAGATGAAGTGCTCCTT	GTAGCTGGATGCCGCCAT
<i>notch1</i>	TACAAGTGCAACTGCCTGCT	GGCAGACACAGGAGAAGCTC
<i>notch2</i>	TCAGCCGGGATACCTATGAG	TTTGCACAGGGATGAGACAG
<i>notch3</i>	CGTGGCTTCTTTCTACTGTGC	CGTTCACCGGATTTGTGTC
<i>jag1</i>	GTCCTAAGCATGGGTCTTGC	GGGTGTGGGATGCACTTATC
<i>jag2</i>	GTCGTCATCCCCTTCCAGT	GGTGGTATCGTTGTCCCAGT
<i>dll1</i>	GAGCGTGGGGAGAAAGTGT	ATGCTGCTCATCACATCCAG
<i>dll4</i>	GCACTCCCTGGCAATGTACT	GGAGTGGTGGGTGCAGTAGT




Figure S1. Non-validated miR expressed in RA and OA patient macrophages. Relative levels of the indicated miR were determined by RT-qPCR in macrophages isolated from RA (n = 11) and OA (n = 14) patients. Values are indicated as relative quantification (RQ), using the sample with the lowest $2^{-\Delta\Delta C_t}$ value (RQ = 1) as reference. Probability values were calculated using the Mann-Whitney U-test.




Figure S2. Notch1 and Notch2 are not differentially expressed in RA and OA macrophages. Relative levels of Notch1 and Notch2 mRNA in macrophages from RA (n = 4) and OA (n = 6) patients, as determined by RT-qPCR. Data shown as mean \pm SEM; p values were calculated using the Mann-Whitney U-test.




Figure S3. IKK α is not differentially expressed in RA and OA macrophages. (a) Relative IKK α mRNA levels in macrophages from RA (n = 12) and OA (n = 14) patients; Mann-Whitney U-test. (b) IKK α staining in RA (n = 13) and OA (n = 8) synovial tissues.




Figure S4. Ingenuity Pathway Analysis of miR-223 targets identified in silico. Number of putative miR-223 target genes for each of the signalling pathways identified by IPA.




Figure S5. Forced miR-223 expression does not affect AHR protein levels. Immunoblot analysis of extracts of HEK-293 cells expressing control or pre-miR-223, probed with anti-AHR and - β -actin antibodies. Bands were densitometred in Image J and the AHR/ β -actin calculated; ratio in mock-transfected cells is equal to 1. Results are representative of two independent experiments




Figure S6. AHR target gene expression in synovial macrophages. Tissue sections from OA and RA patients were double-stained for CYP1B1 (green) and the macrophage marker CD68 (red); merge of both channels (yellow). Images representative of 5 synovial tissues per condition.




Figure S7. Correlation between CYP1A1, miR-223 and Notch3 levels. (a) Linear regression analysis of CYP1B1 mRNA and miR-223 levels in RA and OA samples ($n = 11$). (b) AHR mRNA levels in OA and RA patient samples, as determined by RT-qPCR. (c) Linear regression analysis of CYP1B1 and Notch3 mRNA levels in RA and OA samples ($n = 10$).